Trial reportTopics in antiviral medicine
HIV-Related Cardiovascular Disease, Statins, and the REPRIEVE Trial.
Trial report in Topics in antiviral medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 3 syntheses or guidelines pooled it, 89 citations in OpenAlex.
- Global Burden of Atherosclerotic Cardiovascular Disease in People Living With HIV: Systematic Review and Meta-Analysis.Circulation · 2018Pooled it
- Statin use and all-cause mortality in people living with HIV: a systematic review and meta-analysis.BMC infectious diseases · 2018 · on this mapPooled it
- The association between HIV and atherosclerotic cardiovascular disease in sub-Saharan Africa: a systematic review.BMC public health · 2017Pooled it
- Infectious versus chronic conditions: time to dismantle silos in public health.Lancet regional health. Americas · 2025Review
- Effects of statins beyond lipid-lowering agents in ART-treated HIV infection.Frontiers in immunology · 2024Review
- Effects of Electronic Cigarette Use on Cardiovascular-Disease-Related Inflammatory Biomarkers in Smokers with HIV in a Switching Study in the United States.Pharmacoepidemiology · 2023Article
- Statins Utilization in Adults With HIV: The Treatment Gap and Predictors of Statin Initiation.Journal of acquired immune deficiency syndromes (1999) · 2022Article
- The Role of the Social Determinants of Health on Engagement in Physical Activity or Exercise among Adults Living with HIV: A Scoping Review.International journal of environmental research and public health · 2022Article
- Review
- ApoA-I mimetics favorably impact cyclooxygenase 2 and bioactive lipids that may contribute to cardiometabolic syndrome in chronic treated HIV.Metabolism: clinical and experimental · 2021Article
- Cardiovascular disease and prevention among people living with HIV in South Florida.Medicine · 2021 · on this mapObservational
- Classical monocyte transcriptomes reveal significant anti-inflammatory statin effect in women with chronic HIV.Cardiovascular research · 2021Article
- Cost-effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease among people living with HIV in the United States.Journal of the International AIDS Society · 2021Article
- Article
- A review of serial coronary computed tomography angiography (CTA) to assess plaque progression and therapeutic effect of anti-atherosclerotic drugs.The international journal of cardiovascular imaging · 2020Review
- Immunomodulatory and Anti-Inflammatory Strategies to Reduce Comorbidity Risk in People with HIV.Current HIV/AIDS reports · 2020Review
- Statins for atherosclerotic cardiovascular disease prevention in people living with HIV in Thailand: a cost-effectiveness analysis.Journal of the International AIDS Society · 2020Article
- Excess Risk for Atherosclerotic Cardiovascular Outcomes Among US Adults With HIV in the Current Era.Journal of the American Heart Association · 2020Article
- HIV infection and coronary heart disease: mechanisms and management.Nature reviews. Cardiology · 2019Review
- HIV-Nef Protein Transfer to Endothelial Cells Requires Rac1 Activation and Leads to Endothelial Dysfunction Implications for Statin Treatment in HIV Patients.Circulation research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
HIV infection is associated with increased cardiovascular disease (CVD), and increased rates of myocardial infarction and stroke have been observed in HIV-infected individuals. After traditional risk factors that are more common among people living with HIV infection (such as smoking and diabetes) are accounted for, the excess risk for CVD persists. Recent studies suggest that increased immune activation and inflammation may contribute to excess risk for CVD in the context of HIV infection. Imaging studies in the HIV-infected population have found inflamed, noncalcified plaque that is vulnerable to rupture. Statin therapy may represent a potentially useful primary prevention strategy for CVD in HIV-infected individuals, as this class of drugs lowers lipid levels and may simultaneously reduce immune activation and inflammation. REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) is a large, multicenter study funded by the National Institutes of Health. REPRIEVE will test whether pitavastatin, a newer statin that does not have substantial interactions with antiretroviral drugs, can prevent vascular events over time among HIV-infected individuals who do not have known CVD. This study is now open to enrollment at sites throughout the United States and abroad and will hopefully provide definitive data on this important question.
Indexed as
Identifiers
26713505PMC6148918W2412775484What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.